KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$119.0 million.

  • Nektar Therapeutics' Net Income towards Common Stockholders rose 5.58% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.90% up from last year.
  • Per Nektar Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$119.0 million for FY2024, which was up 56.90% from -$276.1 million recorded in FY2023.
  • Nektar Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$119.0 million during FY2024, with a 5-year trough of -$525.1 million in FY2021.
  • In the last 3 years, Nektar Therapeutics' Net Income towards Common Stockholders had a median value of -$276.1 million in 2023 and averaged -$256.7 million.
  • In the last 5 years, Nektar Therapeutics' Net Income towards Common Stockholders declined by 18.15% in 2021 and then spiked by 56.90% in 2024.
  • Nektar Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$444.4 million in 2020, then decreased by 18.15% to -$525.1 million in 2021, then rose by 28.56% to -$375.1 million in 2022, then rose by 26.41% to -$276.1 million in 2023, then spiked by 56.90% to -$119.0 million in 2024.